Investigation of a tumour enzyme as a predictor of patient response to an Australian anti-cancer drug

GSAO是我们开发的一种新的抗癌药物，目前正在癌症患者身上进行试验。我们对GSAO如何发挥作用的研究表明，它需要被某些类型的癌症表达的一种酶激活。这一发现表明，GSAO对制造这种酶的癌症应该更有效。我们的目标是在实验室实验中确立这一概念，作为选择更有可能从GSAO治疗中受益的患者的基础。

GSAO is a new cancer drug we have developed that is currently being trialed in cancer patients. Our investigation of how GSAO works has revealed that it needs to be activated by an enzyme expressed by certain types of cancers. This finding implies that GSAO should be more effective against cancers that make this enzyme. Our aim is to establish this concept in laboratory based experiments as a basis for selection of patients who are more likely to benefit from GSAO treatment.